Stocks / NYSE / Intrexon Corporation

Intrexon Corporation

Our Opinion


Supporting Evidence: 


“The compounds were subjected to a standardized “proof of concept” animal model evaluating efficacy for reducing clinically relevant C. difficile infection(s) and increased survival relative to vancomycin positive control.” Read the following article

Company Description

Intrexon Corp. operates as a biotechnology company. The company engages in the field of synthetic biology, which is an emerging discipline that applies engineering principles to biological systems. It designs, builds and regulates gene programs, which are DNA sequences that consist of key genetic components by using its suite of proprietary and complementary technologies. The company offers UltraVector proprietary technology platforms for the design, creation, modification, and regulation of complex gene programs and cellular systems at commercial scale; and RTS technology, which provides inducible control over the level and timing of gene expression and is part of an UltraVector library of various diverse modular genetic components. Intrexon was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD. [Source: MarketWatch]

Company Website: